Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

@inproceedings{Moilanen2015DiscoveryOO,
  title={Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies},
  author={Arja Moilanen and Reetta Riikonen and Riikka Oksala and Laura S. Ravanti and Eija Aho and Gerd Wohlfahrt and Pirjo S. Nyk{\"a}nen and Olli P. T{\"o}rm{\"a}kangas and Jorma J. Palvimo and Pekka J. Kallio},
  booktitle={Scientific reports},
  year={2015}
}
Activation of androgen receptor (AR) is crucial for prostate cancer growth. Remarkably, also castration-resistant prostate cancer (CRPC) is dependent on functional AR, and several mechanisms have been proposed to explain the addiction. Known causes of CRPC include gene amplification and overexpression as well as point mutations of AR. We report here the pharmacological profile of ODM-201, a novel AR inhibitor that showed significant antitumor activity and a favorable safety profile in phase 1/2… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 5 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 36 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 55 REFERENCES

an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

  • Fizazi, K. et al. Activity, safety of ODM-201 in patients with progressive metastatic ARADES
  • Lancet Oncol 15, 975–985
  • 2014

Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC)

  • Smith, R M.
  • J Clin Oncol 31 Suppl: abstr
  • 2013

Similar Papers

Loading similar papers…